ClinicalTrials.gg
CompletedNCT00401323Updated Jan 20, 2011

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 2/3 interventional study of docetaxel (XRP6976) and cisplatin in Head and Neck Neoplasms, Neoplasm Recurrence, Local and Neoplasm Metastasis, sponsored by Sanofi. Completed at 20 sites in 20 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-20.

Sponsored by Sanofi · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
568
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies testing docetaxel in Head and Neck Neoplasms — 3 open to participants now, 6 under way, none of them phase 3. Docetaxel · Head and Neck Neoplasms.

Enrollment
Largest of 64
568 · median 34
Started
1998
with 1 other
Phase 2/3
Only one
of the 68
Registered
27th of 68
by date
Lead sponsor
6 of 68
Sanofi

Among the 68 studies testing docetaxel in Head and Neck Neoplasms, this one has the largest enrollment of the 64 interventional ones that give a count, is one of 2 that started in 1998, is the only one in phase 2/3, and was the 27th registered.

Head and Neck Neoplasms

2,713 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

3 of the 68 studies testing docetaxel in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies testing docetaxel in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

03

Conditions studied

  • Head and Neck Neoplasms
  • Neoplasm Recurrence, Local
  • Neoplasm Metastasis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Patients with or cytologically documented squamous cell carcinoma of the head and neck (SCCHN) (eligible primary sites: oral cavity, oropharynx, hypopharyx, or larynx) presenting with locally recurrent and/or disease, with at least 1 unidimensionally or bidimensionally .

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
568 participants (actual)

Study arms

  • Experimental
    docetaxel plus cisplatin

    Taxotere 75 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by cisplatin 75 mg/m² administered as a 30-minute to 3-hour infusion on Day 1

    Drug: docetaxel (XRP6976) · Drug: cisplatin

  • Active comparator
    cisplatin plus 5-FU

    Cisplatin 100 mg/m², 30-minute to 3-hour infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 1000 mg/m²/day from Day 1 to Day 5

    Drug: cisplatin · Drug: 5-fluorouracil (5-FU)

  • Experimental
    docetaxel plus 5-FU

    Taxotere 85 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 750 mg/m²/day from Day 1 to Day 5 Arm only in the phase II part of the study

    Drug: docetaxel (XRP6976) · Drug: 5-fluorouracil (5-FU)

Interventions

06

What researchers measure

Primary outcomes

  1. time to progression

    Time frame: up to 5 years

Secondary outcomes

  1. overall survival, overall response rate (complete response + partial response), duration of response, and time to treatment failure

    Time frame: up to 5 years

07

Study locations

20 sites
  • sanofi-aventis US
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis
    Buenos Aires, Argentina
  • sanofi-aventis, Australia
    Macquarie Park, New South Wales, Australia
  • Sanofi-Aventis
    Vienna, Austria
  • sanofi-aventis, Belgium
    Diegem, Belgium
  • Sanofi-Aventis
    Rio de Janeiro, Brazil
  • sanofi-aventis Canada
    Laval, Quebec, Canada
  • sanofi-aventis, France
    Paris, France
  • sanofi-aventis Germany
    Berlin, Germany
  • sanofi-aventis Greece
    Athens, Greece
  • Sanofi-Aventis
    Basse-Terre, Guadeloupe
  • Sanofi-Aventis Hungaria
    Budapest, Hungary
  • sanofi-aventis Israel
    Natanya, Israel
  • sanofi-aventis Italy
    Milano, Italy
  • Sanofi-Aventis
    Moscow, Russian Federation
  • Sanofi-Aventis
    Saint-Denis, Réunion
  • sanofi-aventis South Africa
    Midrand, South Africa
  • Sanofi-Aventis
    Madrid, Spain
  • sanofi-aventis Switzerland
    Geneva, Switzerland
  • Sanofi-Aventis
    Montevideo, Uruguay
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1998, a primary completion of Jun 2003 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2006
First posted
Nov 20, 2006
Start
Jan 1998
Primary completionActual
Jun 2003
CompletionActual
Jun 2003
Last update
Jan 20, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00401323
Lead sponsor
Sanofi
First posted
Nov 20, 2006
Start date
Jan 1998
Primary completion
Jun 2003
Completion
Jun 2003
Last update
Jan 20, 2011

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Cisplatin · Fluorouracil

Start the discussion